Assessment of the epidemiological trends for prostate cancer using administrative data in Ontario

被引:2
作者
Saad, Fred [1 ]
Bhindi, Bimal [2 ]
Noonan, Krista [3 ]
Ong, Michael
Castellano, Kimberly [4 ]
Kourkounakis, Alexandra [4 ]
Wallis, Christopher J. D. [5 ,6 ,7 ,8 ]
机构
[1] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[2] Univ Calgary, Dept Surg, Sect Urol, Calgary, AB, Canada
[3] Univ British Columbia, BC Canc Surrey, Vancouver, BC, Canada
[4] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[5] Janssen Inc, Toronto, ON, Canada
[6] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN 37235 USA
[7] Mt Sinai Hosp, Dept Surg, Div Urol, Toronto, ON, Canada
[8] Univ Toronto, Toronto, ON, Canada
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2023年 / 17卷 / 04期
关键词
RECOMMENDATIONS; SURVIVAL; CANADA; STAGE;
D O I
10.5489/cuaj.8099
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Studies have shown fluctuations in prostate cancer (PCa) incidence and prevalence over time and by region. Less is known about the most recent epidemiological trends by PCa disease stage. METHODS: This study was a population-based, sequential, cross-sectional analysis that used administrative health data from Ontario, Canada. After inclusion, patients were classified into non-metastatic (nm) PCa and metastatic (m) PCa. The primary study outcome was a description of temporal trends in the incidence and prevalence of PCa over the study period (2010-2019), stratified by disease state. Crude incidence and prevalence rates were estimated for each year in the study period. RESULTS: Overall, there were 131 718 men living with PCa in 2019. The incident cohort contained 86 123 patients with nmPCa (n=65 691, 76.3%), mPCa (n=8431, 9.8%), or unknown stage (n=12 001, 13.9%). The prevalence increased from 216 to 253 per 10 000 men between 2010 and 2019, respectively. Between 2011 and 2014, overall PCa incidence decreased from 20.9 to 15.4 per 10 000 men, followed by an increase to 18.8 per 10 000 in 2018. The nmPCa incidence rate was considerably higher compared with mPCa and followed a trend similar to the overall incidence. In contrast, the incidence rate for mPCa demonstrated a continuous increase from 1.5 per 10 000 in 2010 to 2.4 per 10 000 in 2018. CONCLUSIONS: The overall prevalence of PCa has risen steadily over the last decade, despite fluctuations in nmPCa incidence. The concurrent rise in mPCa and nmPCa requires further study regarding the burden of localized and systemic treatment.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 20 条
  • [1] [Anonymous], 2019, Canadian cancer statistics
  • [2] [Anonymous], US CANC STAT FACTS P
  • [3] Recommendations on screening for prostate cancer with the prostate-specific antigen test
    Bell, Neil
    Gorber, Sarah Connor
    Shane, Amanda
    Joffres, Michel
    Singh, Harminder
    Dickinson, James
    Shaw, Elizabeth
    Dunfield, Lesley
    Tonelli, Marcello
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (16) : 1225 - 1234
  • [4] Canadian cancer statistics advisory committee, 2021, Canadian cancer statistics
  • [5] Trends in Incidence of Metastatic Prostate Cancer in the US
    Desai, Mihir M.
    Cacciamani, Giovanni E.
    Gill, Karanvir
    Zhang, Juanjuan
    Liu, Lihua
    Abreu, Andre
    Gill, Inderbir S.
    [J]. JAMA NETWORK OPEN, 2022, 5 (03)
  • [6] Dickinson James, 2016, CMAJ Open, V4, pE73, DOI 10.9778/cmajo.20140079
  • [7] Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models
    Earnest, Arul
    Evans, Sue M.
    Sampurno, Fanny
    Millar, Jeremy
    [J]. BMJ OPEN, 2019, 9 (08):
  • [8] MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
    Kasivisvanathan, V
    Rannikko, A. S.
    Borghi, M.
    Panebianco, V
    Mynderse, L. A.
    Vaarala, M. H.
    Briganti, A.
    Budaus, L.
    Hellawell, G.
    Hindley, R. G.
    Roobol, M. J.
    Eggener, S.
    Ghei, M.
    Villers, A.
    Bladou, F.
    Villeirs, G. M.
    Virdi, J.
    Boxler, S.
    Robert, G.
    Singh, P. B.
    Venderink, W.
    Hadaschik, B. A.
    Ruffion, A.
    Hu, J. C.
    Margolis, D.
    Crouzet, S.
    Klotz, L.
    Taneja, S. S.
    Pinto, P.
    Gill, I
    Allen, C.
    Giganti, F.
    Freeman, A.
    Morris, S.
    Punwani, S.
    Williams, N. R.
    Brew-Graves, C.
    Deeks, J.
    Takwoingi, Y.
    Emberton, M.
    Moore, C. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1767 - 1777
  • [9] Klotz L, 2009, CUAJ-CAN UROL ASSOC, V3, pS91
  • [10] Incidence and Mortality of Prostate Cancer in Canada during 1992-2010
    Lagace, Francois
    Ghazawi, Feras M.
    Le, Michelle
    Savin, Evgeny
    Zubarev, Andrei
    Powell, Mathieu
    Moreau, Linda
    Sasseville, Denis
    Popa, Ioana
    Litvinov, Ivan, V
    [J]. CURRENT ONCOLOGY, 2021, 28 (01) : 978 - 990